We could not find any results for:
Make sure your spelling is correct or try broadening your search.
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...
L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...
RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...
Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.4 | 0.796812749004 | 50.2 | 51.05 | 49.6 | 185534 | 50.65266866 | DE |
4 | -0.85 | -1.65208940719 | 51.45 | 52.2 | 49.16 | 263559 | 50.97985518 | DE |
12 | -1.5 | -2.87907869482 | 52.1 | 54.8 | 48.58 | 274680 | 51.88821492 | DE |
26 | 1.42 | 2.88735258235 | 49.18 | 54.8 | 47.98 | 246139 | 51.26051651 | DE |
52 | 1.6 | 3.26530612245 | 49 | 54.8 | 47.28 | 237837 | 50.75607951 | DE |
156 | -5.88 | -10.4107648725 | 56.48 | 56.96 | 34.52 | 235762 | 45.63197254 | DE |
260 | 12.6 | 33.1578947368 | 38 | 57.9 | 28.26 | 281448 | 44.98718074 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions